Frequent undesirable effects of Berodual/F UDV are fine tremor of skeletal muscles, nervousness and dryness of the mouth; less frequent are headache, dizziness, tachycardia and palpitations, especially in susceptible patients.
Potentially serious hypokalemia may result from β2-agonist therapy.
As with use of other inhalation therapy, cough, local irritation and less common, inhalation-induced bronchospasm have been reported.
As with other β-agonist-containing products, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. In rare cases, decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.
In individual cases, psychological alterations have been reported under inhalational therapy with β-agonist-containing products.
Ocular accommodation disturbances, gastrointestinal motility disturbances and urinary retention are rare and reversible.
Ocular side effects have been reported (see Precautions).
In rare cases, skin reactions or allergic-type reactions eg, skin rash, angioedema of the tongue, lips and face, and urticaria may occur.